Super Vidalista is a medication that is used for the treatment of male sexual dysfunction, specifically premature ejaculation and erectile dysfunction (ED). This medication is composed of two different active ingredients, daopxetine and tadalafil. Daopxetine is a selective serotonin reuptake inhibitor (SSRI) that is known to delay ejaculation, while tadalafil is a phosphodiesterase type 5 (PDE5) inhibitor that works by relaxing the muscles in the blood vessels, hence improving blood flow to the penis, resulting in a rock-hard erection.
Super Vidalista has an active half-life of 6-24 hours after being taken orally, and it belongs to the classification of SSRI and PDE5 inhibitors. Men are advised to take 40-80mg daily dose of this medication to treat ED and premature ejaculation.
One of the significant advantages of taking Super Vidalista is that it does not cause acne or water retention side effects. However, it is possible to experience headaches, nausea, dizziness, or heartburn after taking this medication. Additionally, high blood pressure may be a possible side effect of Super Vidalista.
Super Vidalista is not hepatotoxic and does not cause aromatization. The active substances involved in producing this medication are daopxetine and tadalafil, each in 80mg doses that are packed together in blister packs of 10 pills. This medication is produced and marketed by Centurion Laboratories, a reputable pharmaceutical company.
In conclusion, Super Vidalista is a potent medication used for the treatment of premature ejaculation and ED. It has a rapid onset of action, and its unique combination of daopxetine and tadalafil makes it effective in treating both conditions. However, the medication should only be taken after consulting a healthcare provider as there can be a myriad of side effects. It is also important to follow the recommended dosage to prevent any unnecessary complications.
Tadalafil 20mg
Dapoxetine 60mg
Anabolic activity index: not a steroid
Androgenic activity index: not a steroid
Reviews
There are no reviews yet.